C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Appendix E. (Continued) Antimicrobial Agent Organism(s) Streptococcus spp. (Continued) Ceftiofur S. equi subsp. zooepidemicus Ceftiofur Streptococcus agalactiae Streptococcus dysgalactiae Streptococcus uberis Ceftiofur S. suis Cephalexin Streptococcus spp. Streptococcus spp. -hemolytic group Streptococcus spp. Streptococcus spp. Cephalothin -hemolytic group Clindamycin Streptococcus spp. Streptococcus spp. -hemolytic group Difloxacin Streptococcus spp. Doxycycline S. equi subsp. equi and equi and subsp. zooepidemicus subsp. zooepidemicus Enrofloxacin Streptococcus spp. Enrofloxacin Streptococcus spp. Enrofloxacin S. equi subsp. equi and equi and subsp. zooepidemicus subsp. zooepidemicus Enrofloxacin S. suis Florfenicol S. suis Marbofloxacin Streptococcus spp. Marbofloxacin Streptococcus spp. Minocycline Streptococcus spp. Orbifloxacin Streptococcus spp. Orbifloxacin Streptococcus spp. Penicillin G Streptococcus spp. Penicillin G S. suis PenicillinS. agalactiae novobiocin S. dysgalactiae S. uberis Pirlimycin S. agalactiae S. dysgalactiae S. uberis Pradofloxacin S. canis Tetracycline S. suis Bordetella bronchiseptica (4) Ampicillin B. bronchiseptica bronchiseptica Florfenicol B. bronchiseptica bronchiseptica Tildipirosin B. bronchiseptica bronchiseptica Tulathromycin B. bronchiseptica bronchiseptica Mannheimia haemolytica (12) Ampicillin M. haemolytica haemolytica Ceftiofur M. haemolytica haemolytica Danofloxacin M. haemolytica haemolytica
Enrofloxacin Florfenicol
©
M. haemolytica haemolytica M. haemolytica haemolytica
Animal Species
Body Site
Supplement Edition/Date of Addition/Revision*
Horses
Resp
M31-S1 (2004)
Cattle
Mastitis
VET01-A3 (2008)
Swine Dogs
Resp SST
M31-A (1999) VET08, 4th ed. (2018)
Dogs
SST
VET01-S2 (2013)
Dogs
SST
VET01-S2 (2013)
Dogs Horses
SST, UTI Resp, SST
M31-A2 (2002) VET08, 4th ed. (2018)
Dogs Cats Horses
Resp, SST, UTI SST Resp, SST
M31-A (1999) M31-A (1999) VET08, 4th ed. (2018)
Swine Swine Dogs Cats Horses Dogs Cats Horses Swine Cattle
Resp Resp SST, UTI SST Resp, SST SST, UTI SST Resp, SST Mastitis
VET01-S2 (2013) M31-S1 (2004) M31-S1 (2004) M31-S1 (2004) VET08, 4th ed. (2018) M31-A2 (2002) M31-A2 (2002) VET01-S2 (2013) VET01S, 3rd ed. (2015) M31-A (1999)
Cattle
Mastitis
M31-A2 (2002)
Cats Swine
Resp, Skin Resp
VET01S, 3rd ed. (2 (2015) VET01-A3 (2008)
Swine Swine Swine Swine
Resp Resp Resp Resp
VET01-S2 (2013) M31-S1 (2004) VET01S, 3rd ed. (2015) VET01-S2 (2013)
Cattle Cattle Cattle
Resp Resp Resp
Cattle Cattle
Resp Resp
VET08, 4th ed. (2018) M31-A (1999) VET08, 4th ed. (2018) – I and R M31-S1 M31-S1 (2004) (2004) – S M31-A (1999) M31-A2 (2002)
Clinical and Laboratory Standards Institute. All rights reserved.
157
9 / s 9 9 n 1 o i e t i c d n i d S A s t t n n i o e E p m e x k l i p d a e n r p e B u p c S p fi 1 i A c 0 T e E p S - V o y r t a s n n i o r i e i s t e v V e R
C L S I V E T 9 0 / 1 s 9 S 9 n 1 o G i e t e i c n d n e d i r S i A s c A t t d n n m i e i n E o p m V e x k l E i T d a p e 0 1 n r p B u S e 3 p c S F p fi 1 i N A c 0 T G e E e p V n S - o e y r i r t c A a s d n n i m o r i i e i n s t V e v E V e T R 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Appendix E. (Continued) Antimicrobial Agent Organism(s) Mannheimia haemolytica (Continued) Gamithromycin . haemolytica Penicillin G . haemolytica Spectinomycin . haemolytica Tetracycline . haemolytica Tildipirosin . haemolytica Tilmicosin . haemolytica Tulathromycin . haemolytica Pasteurella multocida (26) Amoxicillin P. multocida clavulanate Ampicillin P. multocida Ampicillin P. multocida Ampicillin P. multocida Cefazolin P. multocida
Cefovecin Cefpodoxime Ceftiofur Ceftiofur Danofloxacin
P. multocida P. multocida P. multocida P. multocida P. multocida
Enrofloxacin P. multocida Enrofloxacin P. multocida Florfenicol P. multocida Florfenicol P. multocida Gamithromycin P. multocida Penicillin G P. multocida Penicillin G P. multocida Pradofloxacin P. multocida Spectinomycin P. multocida Tetracycline P. multocida Tetracycline P. multocida Tildipirosin P. multocida Tildipirosin P. multocida Tilmicosin P. multocida Tulathromycin P. multocida Tulathromycin P. multocida Actinobacillus pleuropneumoniae (10) Ampicillin A. pleuropneumoniae pleuropneumoniae Ceftiofur A. pleuropneumoniae pleuropneumoniae Enrofloxacin A. pleuropneumoniae pleuropneumoniae Florfenicol A. pleuropneumoniae pleuropneumoniae Gentamicin Actinobacillus spp. Tetracycline A. pleuropneumoniae pleuropneumoniae Tiamulin A. pleuropneumoniae pleuropneumoniae Tildipirosin A. pleuropneumoniae pleuropneumoniae Tilmicosin A. pleuropneumoniae pleuropneumoniae Tulathromycin A. pleuropneumoniae pleuropneumoniae
158
Animal Species
Body Site
Supplement Edition/Date of Addition/Revision*
Cattle Cattle Cattle Cattle Cattle Cattle Cattle
Resp Resp Resp Resp Resp Resp Resp
VET01S, 3rd ed. (2015) VET01-S2 (2013) M31-A2 (2002) VET01-A3 (2008) VET01-S3 (2015) M31-A (1999) VET01-A3 (2008)
Cats
SST, UTI
VET01-S2 (2013)
Cats Cattle Swine Dogs
VET08, 4th ed. (2018) VET08, 4th ed. (2018) VET01-S2 (2013) VET01-S2 (2013)
Cats Dogs Cattle Swine Cattle
SST, UTI Resp Resp Gen, SST, Resp, UTI SST, UTI Wds/Absc Resp Resp Resp
Cattle Swine Cattle Swine Cattle Cattle Swine Cats Cattle Cattle Swine Cattle Swine Swine Cattle Swine
Resp Resp Resp Resp Resp Resp Resp Skin, Resp Resp Resp Resp Resp Resp Resp Resp Resp
Swine Swine Swine Swine Horses Swine Swine Swine Swine Swine
Resp Resp Resp Resp
©
Resp Resp Resp Resp Resp
VET08, 4th ed. (2018) VET01-A3 (2008) M31-A (1999) M31-A (1999) VET08, 4th ed. (2018) – I and R M31-S1 M31-S1 (2004) (2004) – S M31-A (1999) VET01-S2 (2013) M31-A2 (2002) M31-S1 (2004) VET01S, 3rd ed. (2015) VET01-S2 (2013) VET01S, 3rd ed. (2015) VET01S, 3rd ed. (2 (2015) M31-A2 (2002) VET01-A3 (2008) VET01-A3 (2008) VET01S, 3rd ed. (2015) VET01S, 3rd ed. (2015) M31-A2 (2002) VET01-A3 (2008) VET01-S2 (2013) VET01-S2 (2013) M31-A (1999) VET01-S2 (2013) M31-S1 (2004) VET01-S2 (2013) VET01-A3 (2008) M31-A (1999) VET01S, 3rd ed. (2015) M31-A2 (2002) VET01-S2 (2013)
Clinical and Laboratory Standards Institute. All rights reserved.
C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Appendix E. (Continued) Antimicrobial Agent Organism(s) Histophilus somni (10) Ampicillin H. somni Ceftiofur H. somni Enrofloxacin H. somni Florfenicol H. somni Gamithromycin H. somni Penicillin G H. somni Spectinomycin H. somni Tetracycline H. somni Tildipirosin H. somni Tulathromycin H. somni
Animal Species
Cattle Cattle Cattle Cattle Cattle Cattle Cattle Cattle Cattle Cattle
Body Site
Resp Resp Resp Resp Resp Resp Resp Resp Resp Resp
Supplement Edition/Date of Addition/Revision*
VET08, 4th ed. (2018) M31-A (1999) M31-A (1999) M31-A2 (2002) VET01S, 3rd ed. (2015) VET01-S2 (2013) M31-A2 (2002) VET01-A3 (2008) VET01S, 3rd ed. (2015) VET01-A3 (2008)
Abbreviations: gen, genital; GWG, Generic Drug Working Group; I, intermediate; R, resistant; resp, respiratory; SST, skin and soft tissue; UTI, urinary tract infection; wds/absc, wounds and/or abscesses. *
Past editions of the standard (with breakpoint tables included) and supplement include: M31-A (June 1999), M31-A2 (May 2002), M31-S1 (May 2004), VET01-A3 (February 2008), VET01-S2 (July 2013), and VET01S, 3rd ed. (June 2015). † Although canine breakpoints are not available for oxacillin and chloramphenicol, minimal inhibitory concentration distribution data from canine isolates were evaluated by the subcommittee and determined to support human breakpoints for oxacillin against S. pseudintermedius and pseudintermedius and S. schleiferi (see schleiferi (see Table 2C), and h uman breakpoints for chloramphenicol against Enterobacteriaceae against Enterobacteriaceae (see (see Table 2A), Staphylococcus spp. (see Table 2C), Streptococcus spp. Streptococcus spp. (see Table 2D), Enterococcus spp. Enterococcus spp. (see Table 2E), and P. multocida (see multocida (see Table 2H).
©
Clinical and Laboratory Standards Institute. All rights reserved.
159
9 / s 9 9 n 1 o i e t i c d n i d S A s t t n n i o e E p m e x k l i p d a e n r p e B u p c S p fi 1 i A c 0 T e E p S - V o y r t a s n n i o r i e i s t e v V e R
C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Glossary I. Antimicrobial Class and Subclass Designations, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms I y r a s s o l G
Antimicrobial Class Aminocyclitols
Antimicrobial Subc Subcla lass ss(e (es) s)
Aminoglycosides
Ansamycin -lactam combination agents Cephems
Amikacin Gentamicin Kanamycin Neomycin Streptomycin Tobramycin Rifampin Amoxicillin-clavulanate Piperacillin-tazobactam Cephalosporin Ia,b
Cephalosporin IIa,b Cephalosporin IIIa,b
Cephalosporin IVa,b Cephamycinc Carbapenems
Monobactams Folate pathway antagonists
Glycopeptides Lincosamides
160
Anti Antimi micr crob obia iall Agen Agent( t(s) s) Apramycin Spectinomycin
Glycopeptide Lipoglycopeptide
Cefadroxil Cefazolin Cephalexin Cephalothin Cephapirin Cefaclor Cefuroxime Cefoperazone Cefotaxime Cefovecin Cefpodoxime Ceftazidime Ceftiofur Ceftriaxone Cefepime Cefquinome Cefotetan Cefoxitin Doripenem Ertapenem Imipenem Meropenem Aztreonam Ormetoprim Sulfonamides Trimethoprim Trimethoprimsulfamethoxazole Vancomycin Teicoplanin Clindamycin Lincomycin Pirlimycin
©
Anti Antimi micr crob obia iall Resi Resist stan ance ce Mech Mechan anis ism m Enzymatic modification Efflux Target site (ribosome) mutation Enzymatic modification Decreased permeability Target site (ribosome) modification/ mutation Efflux
Target (RNA poly merase) mutation Enzymatic inactivation (-lactamases) Enzymatic inactivation (-lactamases) Decreased permeability Altered penicillin-binding proteins Efflux
Decreased permeability Production of drug-insensitive enzymes Overexpression of sensitive enzymes Efflux Target site (cell wall) modification Target site (ribosome) modification/mutation Enzymatic inactivation Efflux Ribosomal rotection
Clinical and Laboratory Standards Institute. All rights reserved.
C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Glossary I. (Continued) Antimicrobial Class Macrolides:
Antimicrobial Subc Subcla lass ss(e (es) s)
Anti Antimi micr crob obia iall Agen Agent( t(s) s)
14-membered rings
Clarithromycin Erythromycin
15-membered rings
Azithromycin Gamithromycin Tulathromycin
16-membered rings
Spiramycin Tildipirosin Tilmicosin Tylosin Tylvalosin Metronidazole Avilamycin Penicillin Amoxicillin Ampicillin Piperacillin Methicillin Nafcillin Oxacillin Chloramphenicol Florfenicol
Nitroimidazoles Orthosomycins Penicillinsd (penicillinaselabile) Penicillinsd
Penicillind Aminopenicillind Ureidopenicillind Penicillinae-stable penicillinse
Phenicols
Pleuromutilins
Tiamulin Valnemulin
Polyether ionophore Polypeptides
Monensin Narasin Bacitracin Polymyxin Nalidixic acid
Quinolones
Quinolone Fluoroquinolone
©
Ciprofloxacin Danofloxacin Difloxacin Enrofloxacin Marbofloxacin Orbifloxacin Pradofloxacin
Clinical and Laboratory Standards Institute. All rights reserved.
Anti Antimi micr crob obia iall Resi Resist stan ance ce Mech Mechan anis ism m Target site (ribosome) modification/ mutation Decreased permeability Enzymatic inactivation Efflux
Altered drug-activating enzymes enzymes Decreased ribosomal binding Reduced permeability Altered penicillin-binding proteins Enzymatic inactivation (β-lactamases) Efflux Target site (ribosome) modification/mutation Decreased permeability Enzymatic inactivation Efflux Ribosomal protection Target site (ribosome) modification/mutation Decreased permeability Efflux Ribosomal protection Not known Lipopolysaccharide modification Efflux Target (DNA gyrase, Topoisomerase IV) mutation Decreased permeability Efflux Target site protection Enzymatic inactivation
161
I y r a s s o l G
C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
Glossary I. (Continued)
I y r a s s o l G
Antimicrobial Class Streptogramins: Streptogramins A
Streptogramins B
Antimicrobial Subc Subcla lass ss
Anti Antimi micr crob obia iall Agen Agents ts
Virginiamycin M (I) Virginiamycin S
Anti Antimi micr crob obia iall Resi Resist stan ance ce Mech Mechan anis ism m Target site (ribosome) modification/mutation Enzymatic inactivation Efflux Ribosomal protection
Combinations
Virginiamycin M-virginiamycin S = virginiamy virginiamycin cin Tetracyclines Chlortetracycline Efflux Doxycycline Target site (ribosome) Minocycline modification/mutation Oxytetracycline Drug detoxification Tetracycline Ribosomal protection Others Nitrofurantoin Novobiocin Abbreviations: DNA, deoxyribonucleic acid; MRSA, methicillin-resistant methicillin-resistant Staphylococcus aureus; RNA, ribonucleic acid. Footnotes
a.
Cephalosporins I, II, III, and IV are sometimes referred to as first-, second-, third-, and fourth-generation cephalosporins, respectively. Cephalosporins III and IV are also referred to as “extended-spectrum cephalosporins.” This does not imply activity against ESBL-producing gram-negative bacteria.
b.
For all confirmed extended-spectrum -lactamase (ESBL)–producing strains, the test interpretation should be reported as resistant for this antimicrobial class or subclass.
c.
Although often referred to as a second-generation cephalosporin, cephamycins are not included with the other cephalosporins with regard to reporting of ESBL-producing strains.
d.
Penicillinase-labile; Penicillinase-labile; hydrolyzed by staphylococcal penicillinase.
e.
Not hydrolyzed by staphylococcal penicillinase. penicillinase.
162
©
Clinical and Laboratory Standards Institute. All rights reserved.
C L S I V E T 0 1 S G e n e r i c A d m i n V E T 0 1 S 3 F N G e n e r i c A d m i n V E T 0 1 S 3 L N 0 8 / 1 6 / 2 0 1 8
For Use With VET01
VET08, 4th ed.
This page is intentionall i ntentionally y left blank.
©
Clinical and Laboratory Standards Institute. All rights reserved.
163
